Develop and manufacture peptide active pharmaceutical ingredients (APIs) for pharmaceutical and biotechnology companies. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Every year shown ended in profit.
The gap is $32.4M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 37.4× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
The stock trades 43% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 21% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 8% a year on average.
It pays out $0.57 per share each year — regular cash for whoever holds the stock.
The company’s market value is 37 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.